Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
96.4M
-
Shares change
-
+13.2M
-
Total reported value, excl. options
-
$297M
-
Value change
-
+$40.9M
-
Put/Call ratio
-
0.11
-
Number of buys
-
69
-
Number of sells
-
-39
-
Price
-
$3.09
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2024
150 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2024.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 96.4M shares
of 193M outstanding shares and own 49.83% of the company stock.
Largest 10 shareholders include MORGAN STANLEY (21M shares), Whitefort Capital Management, LP (12.9M shares), BlackRock Inc. (11.6M shares), Two Seas Capital LP (8.57M shares), VANGUARD GROUP INC (7.02M shares), GEODE CAPITAL MANAGEMENT, LLC (3.31M shares), ADAR1 Capital Management, LLC (3.29M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3M shares), FourWorld Capital Management LLC (2.97M shares), and STATE STREET CORP (2.93M shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.